MabLyte is a UK-based life science diagnostics company developing kits to analyze the biological activity of monoclonal antibodies and related drugs. Founded by Geoff Hale and Alice Harrison, the company aims to produce a range of analytical kits. Its core product focus is on kits for assessing the biological activity of monoclonal antibodies used in treating human disease. The company raised £150K in funding from Mercia Fund Management via its Mercia Growth Fund 1. MabLyte intends to use the capital to complete development of its first kit. The article does not report any revenue, user, or other operating metrics.

Total raised

$0M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2013